FDA-cleared profile

Vivid E80, Vivid E90, Vivid E95

GE Medical Systems Ultrasound and · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Vivid E80, Vivid E90, and Vivid E95 are general-purpose diagnostic ultrasound systems with specialized cardiac applications for imaging, measurement, display, and analysis across the labeled adult, pediatric, fetal, vascular, procedural, and other ultrasound applications.

Clinical role
Diagnostic ultrasound acquisition, measurement, analysis, reporting, and release-specific assistance under professional control.
Images and patients
Ultrasound · Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; thoracic; and urologic anatomy
Key limitation
Keep in mind: Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Vivid E80, Vivid E90, and Vivid E95 are general-purpose diagnostic ultrasound systems with specialized cardiac applications for imaging, measurement, display, and analysis across the labeled adult, pediatric, fetal, vascular, procedural, and other ultrasound applications.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; thoracic; and urologic anatomy Input: Live or imported ultrasound data from supported probes, host systems, patient studies, and labeled applications.
  • Who uses it?Intended users: Qualified physicians, sonographers, and other trained ultrasound professionals.
  • What does the software produce?Output: Ultrasound images, measurements, calculations, overlays, and reports for professional review.
  • What is its most important limitation?Key limitation: Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.

Clinical takeaway. Clinical role: Vivid E80, Vivid E90, and Vivid E95 are general-purpose diagnostic ultrasound systems with specialized cardiac applications for imaging, measurement, display, and analysis across the labeled adult, pediatric, fetal, vascular, procedural, and other ultrasound applications.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical acoustic output, biocompatibility, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety testing. For the AI algorithm in Easy Auto EF and Easy AFI LV, testing on 135 images from 45 exams, against manual delineations by two certified cardiologists, gave an average dice score of 92% or higher across countries, 91% or higher across scanning views, and 92% or higher across left ventricle volumes. Clinical studies were not required. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Vivid E80, Vivid E90, and Vivid E95 are general-purpose diagnostic ultrasound systems with specialized cardiac applications for imaging, measurement, display, and analysis across the labeled adult, pediatric, fetal, vascular, procedural, and other ultrasound applications.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Diagnostic ultrasound acquisition, measurement, analysis, reporting, and release-specific assistance under professional control.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Live or imported ultrasound data from supported probes, host systems, patient studies, and labeled applications.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Ultrasound images, measurements, calculations, overlays, and reports for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospitals, clinics, offices, operating rooms, and other medical settings within the labeled applications.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified physicians, sonographers, and other trained ultrasound professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical acoustic output, biocompatibility, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety testing. For the AI algorithm in Easy Auto EF and Easy AFI LV, testing on 135 images from 45 exams, against manual delineations by two certified cardiologists, gave an average dice score of 92% or higher across countries, 91% or higher across scanning views, and 92% or higher across left ventricle volumes. Clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Vivid E80 / Vivid E90 / Vivid E95 was evaluated for acoustic output, biocompatibility, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic, and mechanical safety" … "AI Summary of Testing: Easy Auto EF and Easy AFI LV". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical acoustic output, biocompatibility, cleaning and disinfection, and thermal, electrical, electromagnetic and mechanical safety testing. For the AI algorithm in Easy Auto EF and Easy AFI LV, testing on 135 images from 45 exams, against manual delineations by two certified cardiologists, gave an average dice score of 92% or higher across countries, 91% or higher across scanning views, and 92% or higher across left ventricle volumes. Clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Vivid E80 / Vivid E90 / Vivid E95 was evaluated for acoustic output, biocompatibility, cleaning and disinfection effectiveness as well as thermal, electrical, electromagnetic, and mechanical safety" … "AI Summary of Testing: Easy Auto EF and Easy AFI LV". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K220882 FDA evidence package for Vivid E80, Vivid E90, Vivid E95

  • DesignFDA 510(k) substantial-equivalence decision evidence and product verification described in the exact submission.
  • PopulationFetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; thoracic; and urologic anatomy
  • Scopeexact submission
  • Tested versionVivid E80, Vivid E90, Vivid E95 configuration described in K220882
  • IndependenceSponsor or vendor study

K220882

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K220882 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Live or imported ultrasound data from supported probes, host systems, patient studies, and labeled applications.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K220882: Vivid E80, Vivid E90, Vivid E95

  2. Routing

    Source context, not route validation: The exact FDA package describes LAN or wireless connectivity and DICOM capabilities for the Vivid configuration; verify local interface support, patient identity, routing, and archive behavior.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, and archive behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K220882: Vivid E80, Vivid E90, Vivid E95

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Ultrasound images, measurements, calculations, overlays, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K220882: Vivid E80, Vivid E90, Vivid E95

  5. Viewer/worklist/report

    Unresolved route: Ultrasound images, measurements, calculations, overlays, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K220882: Vivid E80, Vivid E90, Vivid E95

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact FDA package describes LAN or wireless connectivity and DICOM capabilities for the Vivid configuration; verify local interface support, patient identity, routing, and archive behavior.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, and archive behavior still require acceptance testing.

Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems, Ultrasound & Primary Care Diagnostics LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
Only qualified physicians, sonographers, and other trained ultrasound professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K220882 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.
  • Exact FDA submission
  • Checked 2026-09-04

Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K220882 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact FDA package describes LAN or wireless connectivity and DICOM capabilities for the Vivid configuration; verify local interface support, patient identity, routing, and archive behavior.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K220882 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Supported probes, host devices, populations, applications, and optional functions vary by exact release; image-quality assessment and clinical interpretation remain with qualified professionals.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. general-purpose diagnostic ultrasound system limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220882
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; thoracic; and urologic anatomy
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-07-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K220882: Vivid E80, Vivid E90, Vivid E95

    U.S. Food and Drug Administration - Published 2022-07-22 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. K220882 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K220446

Versana Balance

GE Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: Versana Balance is a general-purpose diagnostic ultrasound system for imaging, measurement, display, and analysis of the human body and body fluids across the labeled fetal, abdominal, gynecologic, pediatric, small-organ, cardiac, vascular, musculoskeletal, thoracic, and interventional applications.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; thoracic; and urologic anatomy
Decision
2022-05-11
FDA-cleared K220940

EchoPAC Software Only, EchoPAC Plug-in

GE Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: EchoPAC Software Only and EchoPAC Plug-in review and analyze supported GE ultrasound raw data and DICOM ultrasound images, manage patient records, and support reporting for the labeled diagnostic ultrasound applications.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; thoracic; and urologic anatomy
Decision
2022-07-22
FDA-cleared K221147

Vivid T8, Vivid T9

GE Medical Systems Ultrasound and Primary Care Diagnostics

Authorized purpose: Vivid T8 and Vivid T9 are general-purpose diagnostic ultrasound systems with specialized cardiac applications for fetal, abdominal, pediatric, small-organ, cephalic, cardiac, vascular, musculoskeletal, urologic, thoracic, and interventional imaging by trained professionals.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; thoracic; and urologic anatomy
Decision
2022-07-18
FDA-cleared K220975

V8 Diagnostic Ultrasound System, V7 Diagnostic Ultrasound System

Samsung Medison Co., Ltd.

Authorized purpose: V8 and V7 Diagnostic Ultrasound Systems obtain ultrasound images and analyze body fluids for fetal, obstetric, abdominal, gynecologic, intraoperative, pediatric, small-organ, cephalic, transrectal, musculoskeletal, urologic, cardiac, thoracic, vascular, and transesophageal applications by trained healthcare professionals.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal; thoracic; and urologic anatomy
Decision
2022-06-29

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history